Key Takeaways:
Grail Inc. shares plunged $51.32, or 50.55%, after its NHS-Galleri cancer detection trial failed to achieve the primary endpoint of reducing late-stage cancers.
"Investors deserve transparency about material risks that could affect their investments," Joseph E. Levi, a partner at Levi & Korsinsky, said.
The stock closed at $50.21 on Feb. 20, down from $101.53 the prior session, erasing more than $2.2 billion in market value. The company disclosed Feb. 19 that the primary endpoint of a statistically significant reduction in Stage III and IV cancers "was not observed," attributing the miss to a need for longer follow-up time. A securities class action filed in the Northern District of California alleges Grail executives withheld detailed trial data during the class period from May 13, 2025, through Feb. 19, 2026, while promoting favorable metrics including 99.5% specificity and 88% cancer signal-of-origin accuracy.
The lawsuit claims Grail's selective disclosure strategy — touting positive predictive value as "substantially higher" than 43% while concealing internal trendlines — masked the risk that the three-year screening duration was insufficient to prove clinical utility. Investors have until Aug. 4 to seek lead plaintiff appointment.
The 140,000-participant NHS-Galleri trial was designed to show that the blood-based multi-cancer early detection test could shift diagnoses to earlier stages. On the Q1 2025 earnings call, executives said the positive predictive value was "substantially higher" than the 43% seen in the earlier PATHFINDER study but declined to share the exact figure, citing trial integrity. The company later acknowledged that "a longer follow-up time" was probably needed to compare study arms adequately.
The complaint, Robbins v. GRAIL Inc., names the company and certain current and former executives for violations of the Securities Exchange Act of 1934. Levi & Korsinsky and other firms are representing investors on a contingency basis.
The trial failure raises questions about Grail's ability to retain partnerships with health systems like the NHS and secure funding for extended follow-up periods after losing more than half its market capitalization. The company's next catalyst will be the lead plaintiff selection process, with the court deadline set for Aug. 4.
This article is for informational purposes only and does not constitute investment advice.
